1. Scrip
  2. >>Focus On Asia

How Are Japan’s Regenerative Meds Regs Playing Out?

 
• By Ian Haydock

Nearly 18 months has passed since Japan formally adopted ground-breaking new and revised legislation governing the regulation of cell and tissue therapies in November 2014, but how is the new framework working out in practice?

TOKYO - The first two regenerative medicines were conditionally approved under Japan's new laws governing such products last September, suggesting that the nascent regulatory system is at least performing the function of allowing patients to access new therapies in an area which has been designated a flagship technology for the country.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Focus On Asia

More from Scrip

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.